Antibody News and Research RSS Feed - Antibody News and Research

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.
Unique method opens door to development of simple diagnostic tests for myriad diseases

Unique method opens door to development of simple diagnostic tests for myriad diseases

Researchers at the University of Pittsburgh have developed a unique method for detecting antibodies in the blood of patients in a proof-of-principle study that opens the door to development of simple diagnostic tests for diseases for which no microbial cause is known, including auto-immune diseases, cancers and other conditions. [More]
Anti-CPP presence in bloodstream of RA patients correlates with drug response

Anti-CPP presence in bloodstream of RA patients correlates with drug response

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that the presence of an antibody (anti-CPP ) in the bloodstream of patients with rheumatoid arthritis (RA) correlates with response to different drug treatments. [More]
Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra or Remsima). [More]
Study provides insights into new pathways to generate universal vaccine against influenza viruses

Study provides insights into new pathways to generate universal vaccine against influenza viruses

Diverse antibodies induced in humans by vaccination with an avian influenza virus vaccine may offer broader, more durable protection against multiple strains of influenza than today's vaccines typically provide, according to a study led by Florian Krammer, PhD, Assistant Professor in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, and Patrick Wilson, PhD, Associate Professor in the Department of Medicine at the University of Chicago. [More]
New drug for chronic migraine may reduce headache hours in few days

New drug for chronic migraine may reduce headache hours in few days

A new drug to prevent migraine was associated with fewer headache hours for people with chronic migraine within three to seven days after the first injection, according to a study published in the June 8, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Migraine drug has quick onset of action

Migraine drug has quick onset of action

The drug TEV-48125, shown to be effective for chronic migraine in a phase II trial, appears to work within 3 to 7 days of injection, researchers report. [More]
Screening for syphilis in persons at risk for infection provides substantial benefit

Screening for syphilis in persons at risk for infection provides substantial benefit

The U.S. Preventive Services Task Force has found convincing evidence that screening for syphilis infection in asymptomatic, nonpregnant persons at increased risk for infection provides substantial benefit. The report appears in the June 7 issue of JAMA. [More]
Scientists develop non-toxic transplantation procedure using antibodies to target blood stem cells in mice

Scientists develop non-toxic transplantation procedure using antibodies to target blood stem cells in mice

Harvard Stem Cell Institute scientists have taken the first steps toward developing a treatment that would make bone marrow - blood stem cell - transplantation safer and, as a result, more widely available to the millions of people living with blood disorders like sickle cell anemia, thalassemia, and AIDS. [More]
Tanaka develops world's first kit to directly detect ZIKA virus in blood

Tanaka develops world's first kit to directly detect ZIKA virus in blood

Tanaka Holdings Co., Ltd. announced today that Tanaka Kikinzoku Kogyo K.K., which operates the Tanaka Precious Metals manufacturing business, has developed the world's first kit able to directly detect the ZIKA virus in blood. The kit is capable of rapid ZIKV detection in just 10 to 15 minutes. [More]
Eculizumab drug provides new hope for kidney failure patients

Eculizumab drug provides new hope for kidney failure patients

Surgeons at the University of Illinois Hospital & Health Sciences System have — for the first time — used an orphan drug to prevent rejection of a kidney transplanted from a living donor with a mismatched blood type. [More]
Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting. [More]
Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

Antiinflammatory drug HUMIRA enhances specific TNF function in rheumatoid arthritis patients

Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular function of TNF in rheumatoid arthritis patients. [More]
Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

Scientists use X-rays to study how eculizumab prevents immune system from damaging kidney tissue

In collaboration with Alexion Pharmaceuticals, Inc., scientists from Aarhus University have used X-rays to understand how the therapeutic antibody eculizumab prevents our immune system from destroying red blood cells and damaging kidney tissue. [More]
Improved research tool may open door to effective HIV vaccine designs

Improved research tool may open door to effective HIV vaccine designs

Vaccines are usually medicine's best defense against the world's deadliest microbes. However, HIV is so mutable that it has so far effectively evaded both the human immune system and scientists' attempts to make an effective vaccine to protect against it. [More]
IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

Ramucirumab is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. [More]
Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Radiation therapy with bevacizumab/pembrolizumab improves outcomes in glioma patients

Patients with recurrent high-grade glioma brain tumors have few effective treatment options and the majority of available therapies do not improve survival. Moffitt Cancer Center will present preliminary results from a phase 1 study testing whether the addition of pembrolizumab to radiation therapy and bevacizumab is safe and can control tumor growth for these patients. [More]
Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer Center researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago. [More]
Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Despite the known toxic effects of chemotherapy on the heart, the majority of women undergoing breast cancer treatment are not getting the recommended follow-up heart scans, according to research presented at the British Cardiovascular Society Conference in Manchester today. [More]
UZH scientists identify new class of protein compounds to treat HER2-positive breast cancer

UZH scientists identify new class of protein compounds to treat HER2-positive breast cancer

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms of breast cancer, the cells have too much of the receptor HER2 on their surface. [More]
Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Neuroblastoma tumors shrank, some dramatically, in 80 percent of newly diagnosed, young, high-risk patients enrolled in a Phase II clinical trial that included an experimental monoclonal antibody. The immunotherapy agent was produced on the St. Jude Children's Research Hospital campus where the study is still underway. [More]
Advertisement
Advertisement